A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study.

Aortic stenosis Clinical care Health services Prospective registry Quality of care TAVI Transcatheter aortic valve implantation

Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
30 Mar 2024
Historique:
received: 18 07 2023
revised: 23 01 2024
accepted: 27 02 2024
medline: 30 3 2024
pubmed: 30 3 2024
entrez: 30 3 2024
Statut: aheadofprint

Résumé

There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety. Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%). Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries.
METHODS METHODS
This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety.
RESULTS RESULTS
Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%).
CONCLUSIONS CONCLUSIONS
Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.

Identifiants

pubmed: 38554125
pii: 7637935
doi: 10.1093/eurheartj/ehae147
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Institute for Pharmacology and Preventive Medicine GmbH

Investigateurs

Derk Frank (D)
Gemma McCalmont (G)
Peter Bramlage (P)
Claudia M Lüske (CM)
Marie Zielinski (M)
Daniel Greinert (D)
Cornelia Deutsch (C)
Violetta Hachaturyan (V)
Eric Durand (E)
Sandra Lauck (S)
Douglas Muir (D)
Mark Spence (M)
Mariuca Vasa-Nicotera (M)
David Wood (D)
Francesco Saia (F)
Jana Kurucova (J)
Wilbert Wesselink (W)
Radka Rakova (R)
Martin Thoenes (M)
Cristóbal A Urbano-Carrillo (CA)
Carlos Lara García (CL)
Beatriz Chamorro (B)
Damien Bouchayer (D)
Jean-Philippe Claudel (JP)
Hervé Perrier (H)
Viktoria Frebault (V)
Vlad Anton Iliescu (VA)
Catalina Andreea Parasca (CA)
Christophe Saint Etienne (CS)
Katia Lassouani (K)
Florence Leclercq (F)
Wassim Zitouni (W)
Sonia Soltani (S)
Vincent Auffret (V)
Rosalie Le Gal (RL)
Lluis Asmarats (L)
Elena Jimenez Xarrie (EJ)
Carlo Di Mario (C)
Niccolo Ciardetti (N)
Francesco Meucci (F)
Aurelie Veugeois (A)
Imane Bagdadi (I)
Jiri Maly (J)
Lenka Kolinova (L)
Andreas Schober (A)
Georg Delle-Karth (G)
Claudia Schuster (C)
Marie-Christine Leitgeb (MC)
Luis Nombela-Franco (L)
Esther Bernardo García (EB)
María Aránzazu Ortega Pozzi (MAO)
Nikos Werner (N)
Jürgen Leick (J)
Michael Lauterbach (M)
Hannah Waschbüsch (H)
Joan Antoni (J)
Guillem Muntané (G)
Julia Mascherbauer Olga Daxböck (JMO)
Mirela Butkovic (M)
Simona Popescu (S)
Giuseppe Musumeci (G)
Martina Perrero (M)
Nicolas Meneveau (N)
Stephanie Watbled (S)
Thibaud Meurice (T)
Maxence Delomez (M)
Felix Mahfoud (F)
Bruno Scheller (B)
Sebastian Ewen (S)
Ann-Kathrin Berger (AK)
Christina Koch (C)
Alexandra Engel (A)
Federico De Marco (F)
Paolo Olivares (P)
Tim Seidler (T)
Frieder Wolf (F)
Carolin Müller (C)
Maren Hünermund (M)
Florian Leuschner (F)
Mathias Konstandin (M)
Lisa Linz (L)
Hannah Ulbricht (H)
Patrick Joly (P)
Sabrina Siame (S)
Jean-Philippe Collet (JP)
Nassima Ait Amrane (NA)
Ferdinand Vogt (F)
Dow Rosenzweig (D)
Emilio Di Lorenzo (E)
Barbara Cefalo (B)
Elmar Kuhn (E)
Vera Wolf (V)
Vicente Peral Disdier (VP)
Jaume Maristany Daunert (JM)
Maria Carmen de la Bandera Sanchez (MC)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Derk Frank (D)

Department of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), University Clinical Centre Schleswig-Holstein (UKSH), Arnold-Heller Strasse 3, Haus K3, Kiel 24105, Germany.
Department of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), German Centre for Cardiovascular Research, partner site Hamburg/Kiel/Lübeck, Arnold-Heller Strasse 3, Haus K3, Kiel 24105, Germany.

Eric Durand (E)

Department of Cardiology, Univ Rouen Normandie, Inserm U1096, CHU Rouen, Rouen, France.

Sandra Lauck (S)

Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, BC, Canada.

Douglas F Muir (DF)

Cardiology Department, James Cook University Hospital, Middlesbrough, UK.

Mark Spence (M)

Cardiology Department, Mater Private Network, Dublin, Ireland.

Mariuca Vasa-Nicotera (M)

Cardiology Department, Hospital Sindelfingen-Böblingen, Sindelfingen, Germany.

David Wood (D)

Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, BC, Canada.

Francesco Saia (F)

Department of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Cristóbal A Urbano-Carrillo (CA)

Cardiology Department, Hospital Regional Universitario de Málaga, Malaga, Spain.

Damien Bouchayer (D)

Department of Cardiology, The Clinique de l'Infirmerie Protestante, Lyon, France.

Vlad Anton Iliescu (VA)

Department of Cardiology, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.

Christophe Saint Etienne (CS)

Department of Cardiology, Centre Hospitalier Régional Universitaire (CHRU) de Tours, Hôpital Trousseau, Tours, France.

Florence Leclercq (F)

Cardiology Department, Montpellier University Hospital, Montpellier University, Montpellier, France.

Vincent Auffret (V)

Université de Rennes 1, CHU Rennes Service de Cardiologie, Inserm LTSI U1099, Rennes, France.

Lluis Asmarats (L)

Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Carlo Di Mario (C)

Structural Interventional Cardiology Division, Department of Clinical & Experimental Medicine, Careggi University Hospital, Florence, Italy.

Aurelie Veugeois (A)

Department of Cardiology, Institut Mutualiste Montsouris, Paris, France.

Jiri Maly (J)

Cardiac Center, IKEM Prague, Prague, Czech Republic.

Andreas Schober (A)

Department of Cardiology, Hospital Floridsdorf, Vienna, Austria.
Karl Landsteiner Institute for Cardiovascular and Critical Care Research Vienna, Vienna, Austria.

Luis Nombela-Franco (L)

Instituto Cardiovascular, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Nikos Werner (N)

Medical Department III, Heart Center Trier, Krankenhaus der Barmherzigen Brüder, Trier, Germany.

Joan Antoni Gómez-Hospital (JA)

Heart Diseases Institute, Bellvitge University Hospital-IDIBELL, University of Barcelona, Barcelona, Spain.

Julia Mascherbauer (J)

Department of Internal Medicine 3/Cardiology, University Hospital St. Pölten, St. Pölten, Austria.

Giuseppe Musumeci (G)

Struttura Complessa of Cardiology, Ospedale Mauriziano, Torino, Italy.

Nicolas Meneveau (N)

Cardiology, Besancon Regional University Hospital Center, Besancon, France.

Thibaud Meurice (T)

Cardiology, Polyclinique Du Bois, Lille, France.

Felix Mahfoud (F)

Internal Medicine III, Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital of Saarland, Homburg, Germany.

Federico De Marco (F)

Cardiology, Centro Cardiologico Monzino, Milan, Italy.

Tim Seidler (T)

Department of Cardiology and Pulmonology, Georg-August-University, Göttingen, Germany.
Department of Cardiology, University Medicine Göttingen, Heart Center, Göttingen, Germany.
Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany.

Florian Leuschner (F)

Department of Medicine III, University of Heidelberg, German Centre for Cardiovascular Research (DZHK), Heilderberg, Germany.

Patrick Joly (P)

Department of Interventional Cardiology, Hôpital Saint Joseph, Marseille, France.

Jean-Philippe Collet (JP)

Department de Cardiologie, Hôpital de Pitié-Salpêtrière AP-HP, Paris, France.

Ferdinand Vogt (F)

Department for Cardiovascular Surgery, Artemed Klinikum München, München, Germany.

Emilio Di Lorenzo (E)

Division of Cardiology, Department of Cardiovascular Surgery, L'Ospedale S.Giuseppe Moscati di Avellino, Avellino, Italy.

Elmar Kuhn (E)

Department of Cardiothoracic Surgery, Heart Center, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany.

Vicente Peral Disdier (VP)

Cardiology Department, University Hospital Son Espases, Palma de Mallorca, Spain.

Violetta Hachaturyan (V)

Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.

Claudia M Lüske (CM)

Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.

Radka Rakova (R)

Edwards Lifesciences, Prague, Czech Republic.

Wilbert Wesselink (W)

Edwards Lifesciences, Prague, Czech Republic.

Jana Kurucova (J)

Edwards Lifesciences, Prague, Czech Republic.

Peter Bramlage (P)

Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.

Gemma McCalmont (G)

Cardiology Department, James Cook University Hospital, Middlesbrough, UK.
Edwards Lifesciences, Nyon, Switzerland.

Classifications MeSH